X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The grant award will fund a Phase 3 clinical trial, 3K3A-APC, which is a genetically engineered variant of the naturally occurring activated protein C (APC), is proposed to protect the brain following a stroke by reducing bleeding and inflammation.
Lead Product(s): 3K3A-Activated Protein C
Therapeutic Area: Neurology Product Name: 3K3A-APC
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institute of Neurological Disorders and Stroke
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 24, 2022
Details:
ZZ Biotech’s 3K3A-APC is a genetically engineered variant of the naturally occurring activated Protein C, which plays a role in the regulation of blood clotting and inflammation. In animal models of stroke, 3K3A-APC has helped prevent bleeding caused by tPA.
Lead Product(s): 3K3A-APC
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
